||1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Astrogliosis Does Not Require Activation of Ornithine Decarboxylase.
O'Callaghan, J. P. ;
Seidler, F. J. ;
||Health Effects Research Lab., Research Triangle Park, NC. Neurotoxicology Div. ;Duke Univ. Medical Center, Durham, NC. Dept. of Pharmacology.
Ornithine decarboxylase ;
Enzyme activation ;
Glial fibrillary acidic protein ;
Blood-brain barrier ;
Corpus striatum ;
||Some EPA libraries have a fiche copy filed under the call number shown.
||Mechanical injury to the brain results is enhanced immunostaining for glial fibrillary acidic protein (GFAP) that is markedly inhibited by diffuoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxlase. In the current study, systemic exposure of mice to the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), also increased GFAP but, unlike mechanical injury, this increase was not prevented by DFMO pretreatment. These results indicate that de novo polyamine biosynthesis is not obligatory for the MPTP-induced increase in GFAP. MPTP administration, unlike mechanical injury, does not disrupt the blood-brain barrier; thus, a role for polyamine biosynthesis in the astrocyte response to injury may be restricted to insults involving a compromised blood-brain barrier.
||Pub. in Neuroscience Letters 148, n1 and 2 p105-108, 14 Dec 92. See also PB91-145045. Prepared in cooperation with Duke Univ. Medical Center, Durham, NC. Dept. of Pharmacology.
|NTIS Title Notes
||Reprint: 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Astrogliosis Does Not Require Activation of Ornithine Decarboxylase.
||PC A02/MF A01